{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Jolene Diedrich"}, {"accession": "MS:1000589", "name": "contact email", "value": "jdiedrich@salk.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Salk"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Edward Stites"}, {"accession": "MS:1000589", "name": "contact email", "value": "estites@salk.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "IBL-F, Salk Institute for Biological Studies, La Jolla, CA, USA"}]}], "datasetFiles": [{"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180420_ESTM-07_w500fmol.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180420_ESTM-08_w500fmol.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180420_ESTM-09_w500fmol.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180420_ESTM-10_w500fmol.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180420_ESTM-11_w500fmol.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180420_ESTM-12_w500fmol.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180515_ESTM-13_w500fmol.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180515_ESTM-14_w500fmol.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180515_ESTM-15_w500fmol.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180515_ESTM-16_w500fmol.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180515_ESTM-17_w500fmol_2.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180515_ESTM-18_w500fmol.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180614_Ed peptides-13-18_v2.sky"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180614_Ed peptides-13-18_v2.sky.view"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180614_Ed peptides-13-18_v2.skyd"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180614_Ed peptides-7-12.sky"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180614_Ed peptides-7-12.sky.view"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755/20180614_Ed peptides-7-12.skyd"}], "description": "Cancer treatment decisions are increasingly guided by which specific genes are mutated within each patient\u2019s tumor.  For example, agents inhibiting the epidermal growth factor receptor (EGFR) benefit many colorectal cancer (CRC) patients, with the general exception of those whose tumor includes a KRAS mutation.  However, among the various KRAS mutations, the G13D mutation behaves differently; for unknown reasons, CRC patients with the KRAS G13D mutation (also written KRASG13D) appear to benefit from the EGFR-blocking antibody cetuximab.  Controversy surrounds this observation, because it appears to contradict the well-established mechanisms of EGFR signaling and of RAS mutations.  Here, we identified a systems-level, mechanistic basis that explains why KRASG13D cancers respond to EGFR inhibition.  We first investigated the problem with a computational model of RAS signaling, which unexpectedly revealed that the known biophysical differences between the three most common KRAS mutant proteins are sufficient to generate different sensitivities to inhibition.  Computation and experimentation together revealed a non-intuitive, mutant-specific dependency of wild-type RAS activation by EGFR that is determined by the interaction strength between KRAS and the tumor suppressor neurofibromin (NF1).  KRAS mutants that strongly interact with NF1 drive wild-type RAS activation in an EGFR independent manner through competitive inhibition of NF1, whereas KRAS G13D cells remain dependent upon EGFR for wild-type Ras activation because they cannot competitively inhibit NF1 due to a weak interaction between these two proteins. Overall, our work demonstrates how systems approaches enable mechanism-based inference in genomic medicine and can help identify patients for selective therapeutic strategies.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD014755"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD014755"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD014755"}], "instruments": [{"accession": "MS:1002416", "name": "Orbitrap Fusion"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "Systems approaches reveal why cancer patients with one specific KRAS mutation respond to EGFR inhibitors, thus resolving a problem in cancer personalized medicine."}], "modifications": [{"accession": "MS:1002864", "name": "No PTMs are included in the dataset"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "31551296"}, {"accession": "MS:1002866", "name": "Reference", "value": "McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, Moresco JJ, Shaw AS, Stites EC. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy. Sci Signal. 2019 12(600)"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "A Systems Mechanism for  KRAS Mutant Allele Specific Responses to Targeted Therapy"}